Flecainide was recently shown to possess antiarrhythmic properties in CPVT through either a stabilizing effect on RyR2 by decreasing its opening probability or by increasing the threshold for triggered activity through its Na+ channel blocking activity (Lieve et al., 2016; Roston et al., 2017). Here, RYR2 is linked to catecholaminergic polymorphic ventricular tachycardia.